Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study

NCT06820762 is registered in ClinicalTrials.gov with The Second Affiliated Hospital of Dalian Medical University as lead sponsor.

NCT NCT06820762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06820762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study
Lead sponsor
The Second Affiliated Hospital of Dalian Medical University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 28, 2025
Completion date
December 31, 2027
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

sclc